These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 38284703

  • 21. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy.
    Spena G, Moretti TB, Dávila FS, Dos Anjos G, Khan I, Calace FP, Aveta A, Pandolfo SD, Tufano A, Izzo A, Farias A, Perdonà S, Maes K.
    Minerva Urol Nephrol; 2024 Aug; 76(4):467-473. PubMed ID: 39051893
    [Abstract] [Full Text] [Related]

  • 22. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C.
    Radiat Oncol; 2018 Mar 02; 13(1):37. PubMed ID: 29499730
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.
    Singh B, Sharma S, Bansal P, Hooda M, Singh H, Parihar AS, Kumar A, Watts A, Mohan R, Singh SK.
    Nucl Med Commun; 2021 May 01; 42(5):482-489. PubMed ID: 33395191
    [Abstract] [Full Text] [Related]

  • 24. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
    Eur Urol Oncol; 2022 Oct 01; 5(5):544-552. PubMed ID: 32958451
    [Abstract] [Full Text] [Related]

  • 25. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF.
    Clin Nucl Med; 2018 Dec 01; 43(12):e422-e427. PubMed ID: 30273204
    [Abstract] [Full Text] [Related]

  • 26. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
    Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G.
    Minerva Urol Nefrol; 2018 Oct 01; 70(5):462-478. PubMed ID: 29664244
    [Abstract] [Full Text] [Related]

  • 27. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
    Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.
    JAMA Oncol; 2019 Jun 01; 5(6):856-863. PubMed ID: 30920593
    [Abstract] [Full Text] [Related]

  • 28. Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
    Çelen S, Gültekin A, Özlülerden Y, Mete A, Sağtaş E, Ufuk F, Yüksel D, Yağcı B, Zümrütbaş AE.
    Urol Int; 2020 Jun 01; 104(9-10):684-691. PubMed ID: 32750695
    [Abstract] [Full Text] [Related]

  • 29. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
    Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A.
    Nucl Med Commun; 2017 Nov 01; 38(11):956-963. PubMed ID: 28922335
    [Abstract] [Full Text] [Related]

  • 30. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan 01; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
    Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.
    Lancet Oncol; 2019 Sep 01; 20(9):1286-1294. PubMed ID: 31375469
    [Abstract] [Full Text] [Related]

  • 36. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 37. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O, Yavuzsan AH, Arican P, Kirecci SL.
    J Cancer Res Ther; 2021 Jul 15; 17(6):1351-1357. PubMed ID: 34916365
    [Abstract] [Full Text] [Related]

  • 38. Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
    Hu X, Wu Y, Yang P, Wang J, Wang P, Cai J.
    Int Braz J Urol; 2022 Jul 15; 48(6):891-902. PubMed ID: 34003611
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management.
    Afaq A, Alahmed S, Chen SH, Lengana T, Haroon A, Payne H, Ahmed H, Punwani S, Sathekge M, Bomanji J.
    J Nucl Med; 2018 Jan 15; 59(1):89-92. PubMed ID: 28747520
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.